Heidi V. Russell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heidi V. Russell has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Donna Rill
Department of Pediatrics, Center for Cell and Gene Therapy
2 shared publicationsDouglas Strother
Department of Pediatrics, Texas Children's Cancer Center
2 shared publicationsEdwina Popek
Department of Pathology, Baylor College of Medicine, Houston, TX
2 shared publicationsEric Yvon
Department of Pediatrics, Center for Cell and Gene Therapy
2 shared publicationsEttore Biagi
Department of Pediatrics, Center for Cell and Gene Therapy
2 shared publicationsMalcolm Brenner
Department of Pediatrics, Center for Cell and Gene Therapy
2 shared publications
Latest Publications
- 25 August 2010
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 55 (4) , 736-738
Refractory dilated cardiomyopathy associated with metastatic neuroblastoma
A 2‐year‐old African American male presented with heart failure and an abdominal mass. Computerized tomography (CT) scan revealed a 7 cm adrenal lesion, confirmed as poorly differentiated neuroblastoma (NB). CT and meta‐iodobenzoguanidine (MIBG) scans identified multiple metastases, but cardiac MIBG imaging was absent. Cardiac ejection fraction (EF) was 8% with 7% shortening fraction. The patient underwent six cycles of chemotherapy and investigational immunotherapy. Cardiac function improved to 26% EF. However, the tumor proved unresponsive to treatment. The patient died from stage IV congestive heart failure (CHF) and progressive NB. Autopsy confirmed dilated cardiomyopathy with endocardial fibroelastosis. Pediatr Blood Cancer. 2010;55:736–738.
- 25 August 2010
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 55 (4) , 736-738
Refractory dilated cardiomyopathy associated with metastatic neuroblastoma
A 2‐year‐old African American male presented with heart failure and an abdominal mass. Computerized tomography (CT) scan revealed a 7 cm adrenal lesion, confirmed as poorly differentiated neuroblastoma (NB). CT and meta‐iodobenzoguanidine (MIBG) scans identified multiple metastases, but cardiac MIBG imaging was absent. Cardiac ejection fraction (EF) was 8% with 7% shortening fraction. The patient underwent six cycles of chemotherapy and investigational immunotherapy. Cardiac function improved to 26% EF. However, the tumor proved unresponsive to treatment. The patient died from stage IV congestive heart failure (CHF) and progressive NB. Autopsy confirmed dilated cardiomyopathy with endocardial fibroelastosis. Pediatr Blood Cancer. 2010;55:736–738.
- 1 April 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (1) , 23-27
Infantile fibrosarcoma: Clinical and histologic responses to cytotoxic chemotherapy
Background: Infantile fibrosarcoma (IF) is a rare soft tissue sarcoma that presents either at birth or in the first year of life. Complete surgical resection is usually curative but chemotherapy may shrink the tumor to facilitate complete resection. This report describes the histologic changes and outcomes in four patients with IF treated with chemotherapy and surgical resection.Procedure: A retrospective review was performed of patients treated between 2000 and 2007.Results: All four patients are alive with excellent functional outcomes. The patients were diagnosed from birth up to 7 months of age; three had lower extremity tumors and one had a neck tumor. All patients received vincristine, cyclophosphamide, and actinomycin; one patient also received ifosfamide and etoposide after tumor progression. One tumor, arising from the neck, had rapid shrinkage. Two lower extremity tumors had only modest changes in dimensions but upon resection, the tumor bed contained fibrous tissue with exaggerated small caliber vessels. The fourth infant developed metastatic lesions in the central nervous system, orbits, lungs, and kidney after complete removal of the primary tumor. The metastatic lesions responded to chemotherapy and have remained stable for over 3 years.Conclusions: IF is a chemosensitive tumor. In patients where a clinical response is not apparent, cytoreduction of the tumor and replacement with fibrotic and fibrovascular tissue may facilitate gross‐total resection. The chemotherapy‐responsiveness of this tumor may abrogate unfavorable features such as metastatic or residual tumor. Pediatr Blood Cancer 2009;53:23–27.
- 1 April 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (1) , 23-27
Infantile fibrosarcoma: Clinical and histologic responses to cytotoxic chemotherapy
Background: Infantile fibrosarcoma (IF) is a rare soft tissue sarcoma that presents either at birth or in the first year of life. Complete surgical resection is usually curative but chemotherapy may shrink the tumor to facilitate complete resection. This report describes the histologic changes and outcomes in four patients with IF treated with chemotherapy and surgical resection.Procedure: A retrospective review was performed of patients treated between 2000 and 2007.Results: All four patients are alive with excellent functional outcomes. The patients were diagnosed from birth up to 7 months of age; three had lower extremity tumors and one had a neck tumor. All patients received vincristine, cyclophosphamide, and actinomycin; one patient also received ifosfamide and etoposide after tumor progression. One tumor, arising from the neck, had rapid shrinkage. Two lower extremity tumors had only modest changes in dimensions but upon resection, the tumor bed contained fibrous tissue with exaggerated small caliber vessels. The fourth infant developed metastatic lesions in the central nervous system, orbits, lungs, and kidney after complete removal of the primary tumor. The metastatic lesions responded to chemotherapy and have remained stable for over 3 years.Conclusions: IF is a chemosensitive tumor. In patients where a clinical response is not apparent, cytoreduction of the tumor and replacement with fibrotic and fibrovascular tissue may facilitate gross‐total resection. The chemotherapy‐responsiveness of this tumor may abrogate unfavorable features such as metastatic or residual tumor. Pediatr Blood Cancer 2009;53:23–27.
- 1 November 2008
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 31 (9) , 812-819
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma
Autologous neuroblastoma (NB) tumor cells modified to secrete interleukin (IL)-2 (auto–IL-2) can be safely given to patients with advanced neuroblastoma and generate antitumor immune responses. As the benefits of tumor immunization may be greater in patients with minimal residual disease and thus rely on surrogate markers such as immune responses to measure effect, we studied the frequency of immune changes associated with vaccination. Thirteen patients (8 in first remission and 5 after treatment for recurrent NB) received 5 to 8 subcutaneous injections of auto–IL-2 at 0.3×108 cells/kg. The vaccine was well tolerated. Injection site biopsies revealed increased cellularity caused by infiltration of CD4+ and CD8+ lymphocytes, eosinophils, and dendritic cells. Enzyme-linked immunosorbent spot assays for interferon-γ and IL-5 demonstrated that vaccination produced a rise in circulating CD4+ and CD8+ T cells responsive to stimulation by autologous tumor cells. Median event-free survival was 22 months for patients in first remission and 3 months for all others. Four patients treated in first remission remain alive and 3 without disease recurrence.
- 1 November 2008
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 31 (9) , 812-819
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma
Autologous neuroblastoma (NB) tumor cells modified to secrete interleukin (IL)-2 (auto–IL-2) can be safely given to patients with advanced neuroblastoma and generate antitumor immune responses. As the benefits of tumor immunization may be greater in patients with minimal residual disease and thus rely on surrogate markers such as immune responses to measure effect, we studied the frequency of immune changes associated with vaccination. Thirteen patients (8 in first remission and 5 after treatment for recurrent NB) received 5 to 8 subcutaneous injections of auto–IL-2 at 0.3×108 cells/kg. The vaccine was well tolerated. Injection site biopsies revealed increased cellularity caused by infiltration of CD4+ and CD8+ lymphocytes, eosinophils, and dendritic cells. Enzyme-linked immunosorbent spot assays for interferon-γ and IL-5 demonstrated that vaccination produced a rise in circulating CD4+ and CD8+ T cells responsive to stimulation by autologous tumor cells. Median event-free survival was 22 months for patients in first remission and 3 months for all others. Four patients treated in first remission remain alive and 3 without disease recurrence.
- 1 February 2007
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 30 (2) , 227-233
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin
In murine models, transgenic chemokine-cytokine tumor vaccines overcome many of the limitations of single-agent immunotherapy by producing the sequence of T-cell attraction followed by proliferation of tumor antigen-activated clones. The safety and immunologic effects of this approach in humans were tested in 7 patients with relapsed or refractory neuroblastoma. They each received up to 8 subcutaneous injections of a vaccine combining lymphotactin—and interleukin-2 (IL-2)—secreting autologous neuroblastoma cells in a dose-escalating scheme. Adverse events were limited to grade 1 or 2 localized reactions in all patients, pain in 3 patients, and fever in 3 patients. Injection site biopsies revealed increased cellularity caused by infiltration of CD4+ and CD8+ lymphocytes, eosinophils, and dendritic cells with a decrease in dendritic cells from the first to the second vaccination. Systemically, vaccine was associated with increased tumor recognition as measured by enzyme-linked immunosorbent spot assays. Two patients had interferon-γ predominant responses and 3 had IL-5 predominant responses. Only 1 patient received all 8 injections, 1 patient stopped the study early, and all other patients progressed before completion of the study. Hence, autologous tumor cell vaccines combining transgenic lymphotactin with IL-2 seem to have little toxicity in humans and can induce an antitumor immune response. In this setting, the immune response was insufficient to overcome active recurrent neuroblastoma.
- 1 February 2007
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 30 (2) , 227-233
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin
In murine models, transgenic chemokine-cytokine tumor vaccines overcome many of the limitations of single-agent immunotherapy by producing the sequence of T-cell attraction followed by proliferation of tumor antigen-activated clones. The safety and immunologic effects of this approach in humans were tested in 7 patients with relapsed or refractory neuroblastoma. They each received up to 8 subcutaneous injections of a vaccine combining lymphotactin—and interleukin-2 (IL-2)—secreting autologous neuroblastoma cells in a dose-escalating scheme. Adverse events were limited to grade 1 or 2 localized reactions in all patients, pain in 3 patients, and fever in 3 patients. Injection site biopsies revealed increased cellularity caused by infiltration of CD4+ and CD8+ lymphocytes, eosinophils, and dendritic cells with a decrease in dendritic cells from the first to the second vaccination. Systemically, vaccine was associated with increased tumor recognition as measured by enzyme-linked immunosorbent spot assays. Two patients had interferon-γ predominant responses and 3 had IL-5 predominant responses. Only 1 patient received all 8 injections, 1 patient stopped the study early, and all other patients progressed before completion of the study. Hence, autologous tumor cell vaccines combining transgenic lymphotactin with IL-2 seem to have little toxicity in humans and can induce an antitumor immune response. In this setting, the immune response was insufficient to overcome active recurrent neuroblastoma.